Display options
Cite
Shi J, Liu F, Song Y. Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer. Cancer Manag Res. 2020;12:9375-9387doi: 10.2147/CMAR.S272685.
Shi, J., Liu, F., & Song, Y. (2020). Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer. Cancer management and research, 129375-9387. https://doi.org/10.2147/CMAR.S272685
Shi, Jinhong, et al. "Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer." Cancer management and research vol. 12 (2020): 9375-9387. doi: https://doi.org/10.2147/CMAR.S272685
Shi J, Liu F, Song Y. Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer. Cancer Manag Res. 2020 Sep 30;12:9375-9387. doi: 10.2147/CMAR.S272685. eCollection 2020. PMID: 33061626; PMCID: PMC7533235.
Copy Download .nbib Format: NLM
Share it on

Cancer Manag Res. 2020 Sep 30;12:9375-9387. doi: 10.2147/CMAR.S272685. eCollection 2020.

Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer.

Cancer management and research

Jinhong Shi, Feiqi Liu, Yanqiu Song

Affiliations

  1. Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, People's Republic of China.

PMID: 33061626 PMCID: PMC7533235 DOI: 10.2147/CMAR.S272685

Abstract

Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, accounting for approximately 15% of cases, and is defined by the lack of expression of hormone receptors (estrogen and progesterone receptors) and lack of amplification or overexpression of human epidermal growth receptor 2 (HER2). Due to the lack of targets of hormone receptors and HER2, treatment of TNBC or advanced TNBC relies on conventional chemotherapeutic agents, but their efficacy and prognosis are poor. In patients with advanced TNBC, poorer outcomes are observed. Recently, with the launch of clinical trials and advancements in molecular studies, targeted therapy for signaling transduction pathways, immunotherapy for immune checkpoints, and new chemotherapy strategies have provided feasible or potential therapeutic options for advanced TNBC. This review aimed to summarize recent progress in targeted therapy, immunotherapy, and chemotherapy for advanced TNBC.

© 2020 Shi et al.

Keywords: advanced TNBC; immune checkpoint inhibitor; refractory; targets

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

  1. Cancer Cell. 2015 Apr 13;27(4):450-61 - PubMed
  2. Cancer. 2007 May 1;109(9):1721-8 - PubMed
  3. Clin Cancer Res. 2019 May 1;25(9):2717-2724 - PubMed
  4. Eur J Cancer. 2019 May;112:57-65 - PubMed
  5. Ann Oncol. 2016 Aug;27(8):1525-31 - PubMed
  6. J Oncol. 2020 Mar 9;2020:9258396 - PubMed
  7. N Engl J Med. 2018 Nov 29;379(22):2108-2121 - PubMed
  8. Breast Cancer Res. 2020 Mar 23;22(1):31 - PubMed
  9. Oncotarget. 2015 Mar 10;6(7):5449-64 - PubMed
  10. Am J Pathol. 2017 Mar;187(3):654-664 - PubMed
  11. Ann Oncol. 2018 Jan 1;29(1):154-161 - PubMed
  12. Horm Cancer. 2015 Dec;6(5-6):206-13 - PubMed
  13. Clin Cancer Res. 2018 Jun 15;24(12):2804-2811 - PubMed
  14. Cancer Chemother Pharmacol. 2019 Nov;84(5):977-986 - PubMed
  15. Ther Adv Med Oncol. 2020 Jan 28;12:1758835919897546 - PubMed
  16. Clin Cancer Res. 2007 Apr 15;13(8):2329-34 - PubMed
  17. J Clin Oncol. 2014 Jul 10;32(20):2142-50 - PubMed
  18. Carcinogenesis. 2017 Sep 1;38(9):900-909 - PubMed
  19. J Clin Oncol. 2016 Jul 20;34(21):2460-7 - PubMed
  20. Cancer Discov. 2012 Jun;2(6):524-39 - PubMed
  21. J Natl Cancer Inst. 2014 Jan;106(1):djt319 - PubMed
  22. BMC Cancer. 2020 Jul 16;20(1):661 - PubMed
  23. CA Cancer J Clin. 2020 Jan;70(1):7-30 - PubMed
  24. Mod Rheumatol. 2006;16(2):68-74 - PubMed
  25. Nature. 2012 Oct 4;490(7418):61-70 - PubMed
  26. Annu Rev Med. 2015;66:455-70 - PubMed
  27. Ann Oncol. 2016 May;27(5):812-8 - PubMed
  28. Lancet Oncol. 2020 Jan;21(1):44-59 - PubMed
  29. JAMA Oncol. 2019 Mar 1;5(3):334-342 - PubMed
  30. Nat Commun. 2020 Apr 3;11(1):1669 - PubMed
  31. Cell Death Differ. 2018 Dec;25(12):2209-2220 - PubMed
  32. Nat Rev Clin Oncol. 2018 Sep;15(9):564-576 - PubMed
  33. J Clin Oncol. 2014 Nov 20;32(33):3705-15 - PubMed
  34. N Engl J Med. 2007 Dec 27;357(26):2666-76 - PubMed
  35. Ann Oncol. 2019 Mar 1;30(3):397-404 - PubMed
  36. Nature. 2005 Apr 14;434(7035):913-7 - PubMed
  37. Redox Biol. 2020 Jul;34:101564 - PubMed
  38. Am J Cancer Res. 2016 Sep 01;6(9):1864-1872 - PubMed
  39. Breast Cancer Res Treat. 2018 Feb;167(3):671-686 - PubMed
  40. Cancer Immunol Res. 2014 Apr;2(4):361-70 - PubMed
  41. J Exp Med. 2020 Mar 2;217(3): - PubMed
  42. Clin Cancer Res. 2013 Oct 1;19(19):5505-12 - PubMed
  43. Clin Cancer Res. 2016 Jun 15;22(12):2855-64 - PubMed
  44. Arch Gynecol Obstet. 2020 Jun;301(6):1493-1502 - PubMed
  45. Int J Cancer. 2020 Jul 1;147(1):230-243 - PubMed
  46. Hered Cancer Clin Pract. 2015 Jan 17;13(1):4 - PubMed
  47. Cancer Cell. 2011 Jul 12;20(1):119-31 - PubMed
  48. PLoS One. 2018 Jun 18;13(6):e0196909 - PubMed
  49. Future Oncol. 2019 Jun;15(17):1951-1961 - PubMed
  50. Oncogene. 2005 Nov 14;24(50):7455-64 - PubMed
  51. Int J Biol Sci. 2019 Jan 1;15(3):522-532 - PubMed
  52. Breast. 2016 Oct;29:241-50 - PubMed
  53. J Cell Mol Med. 2020 Mar;24(5):3117-3127 - PubMed
  54. Cancers (Basel). 2017 Feb 24;9(3): - PubMed
  55. Breast Cancer Res. 2014 Aug 08;16(4):406 - PubMed
  56. Clin Cancer Res. 2015 Nov 1;21(21):4780-5 - PubMed
  57. Oncogene. 2010 Jul 15;29(28):4018-32 - PubMed
  58. Am J Surg Pathol. 2017 Mar;41(3):334-342 - PubMed
  59. JAMA Oncol. 2017 Apr 1;3(4):509-515 - PubMed
  60. Cancer Treat Rev. 2013 Aug;39(5):541-50 - PubMed
  61. Cancer Treat Rev. 2015 Jun;41(6):547-53 - PubMed
  62. Lancet. 2011 Mar 12;377(9769):914-23 - PubMed
  63. J Immunother Cancer. 2020 May;8(1): - PubMed
  64. N Engl J Med. 2017 Aug 10;377(6):523-533 - PubMed
  65. Ann Oncol. 2018 Aug 1;29(8):1634-1657 - PubMed
  66. J Clin Oncol. 2008 Oct 1;26(28):4563-71 - PubMed
  67. Cell Commun Signal. 2020 Jan 27;18(1):13 - PubMed
  68. J Clin Oncol. 2018 Mar 20;36(9):884-890 - PubMed
  69. J Clin Oncol. 2015 Feb 1;33(4):304-11 - PubMed
  70. Ann Oncol. 2013 Nov;24(11):2773-80 - PubMed
  71. Breast Cancer Res Treat. 2019 Apr;174(3):615-625 - PubMed
  72. Ann Oncol. 2019 Apr 1;30(4):558-566 - PubMed
  73. Clin Breast Cancer. 2019 Apr;19(2):e283-e296 - PubMed
  74. Oncologist. 2020 May 26;: - PubMed
  75. Neoplasia. 2018 May;20(5):478-488 - PubMed
  76. J Clin Oncol. 2020 Feb 10;38(5):423-433 - PubMed
  77. Clin Cancer Res. 2020 Feb 1;26(3):608-622 - PubMed
  78. Int J Biol Sci. 2016 Dec 7;12(12):1568-1577 - PubMed
  79. JAMA Oncol. 2019 Jan 1;5(1):74-82 - PubMed
  80. Ann Oncol. 2019 Mar 1;30(3):405-411 - PubMed
  81. Trends Pharmacol Sci. 2010 Aug;31(8):372-80 - PubMed
  82. J Clin Oncol. 2015 Feb 20;33(6):594-601 - PubMed
  83. Sci Adv. 2020 Feb 19;6(8):eaaw9960 - PubMed
  84. Breast. 2013 Oct;22(5):650-6 - PubMed
  85. Cancer Lett. 2020 Jul 10;482:102-111 - PubMed
  86. J Clin Oncol. 2008 Sep 10;26(26):4282-8 - PubMed
  87. Ann Oncol. 2018 Sep 1;29(9):1939-1947 - PubMed
  88. Lancet Oncol. 2017 Mar;18(3):371-383 - PubMed
  89. N Engl J Med. 2018 Aug 23;379(8):753-763 - PubMed
  90. Int J Oncol. 2016 Mar;48(3):869-85 - PubMed
  91. J Clin Invest. 2011 Jul;121(7):2750-67 - PubMed
  92. Clin Breast Cancer. 2018 Feb;18(1):88-94 - PubMed
  93. Lancet Oncol. 2017 Oct;18(10):1360-1372 - PubMed
  94. Cancer Res. 2006 Aug 15;66(16):8297-308 - PubMed
  95. Breast Cancer Res Treat. 2018 Jun;169(3):397-406 - PubMed

Publication Types